BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi

Key Takeaways BMY secured EC approval for Breyanzi to treat relapsed or refractory MCL after at least two prior therapies.TRANSCEND NHL 001 showed 82.7% response and 71.6% complete response in heavily pretreated MCL patients.Half of treated patients remained in response at 24 months, supporting sustained benefits for this population.Bristol Myers Squibb (BMY) obtained the European Commission’s (“EC”) approval for a label expansion of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric an ...